These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29368620)

  • 41. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
    Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL
    JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
    Warth A
    Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
    Fumagalli D; Gavin PG; Taniyama Y; Kim SI; Choi HJ; Paik S; Pogue-Geile KL
    BMC Cancer; 2010 Mar; 10():101. PubMed ID: 20233444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of common somatic mutations of EGFR, KRAS, BRAF, NRAS in pulmonary non-small cell carcinoma using iPLEX® HS, a new highly sensitive assay for the MassARRAY® System.
    Sutton BC; Birse RT; Maggert K; Ray T; Hobbs J; Ezenekwe A; Kazmierczak J; Mosko M; Kish J; Bullock A; Shi Z; Stack MS; Irwin D
    PLoS One; 2017; 12(9):e0183715. PubMed ID: 28926605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
    Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
    Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.
    Tafe LJ; Pierce KJ; Peterson JD; de Abreu F; Memoli VA; Black CC; Pettus JR; Marotti JD; Gutmann EJ; Liu X; Shirai K; Dragnev KH; Amos CI; Tsongalis GJ
    Neoplasia; 2016 Sep; 18(9):577-83. PubMed ID: 27659017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
    Breitenbuecher F; Hoffarth S; Worm K; Cortes-Incio D; Gauler TC; Köhler J; Herold T; Schmid KW; Freitag L; Kasper S; Schuler M
    PLoS One; 2014; 9(1):e85350. PubMed ID: 24465542
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET).
    Jaremko M; Justenhoven C; Abraham BK; Schroth W; Fritz P; Brod S; Vollmert C; Illig T; Brauch H
    Hum Mutat; 2005 Mar; 25(3):232-8. PubMed ID: 15706592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
    Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction.
    Kanaji N; Bandoh S; Ishii T; Kushida Y; Haba R; Kohno K; Dobashi H; Ohnishi H; Matsunaga T
    Mol Diagn Ther; 2011 Dec; 15(6):353-9. PubMed ID: 22117119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral brush biopsy analysis by matrix assisted laser desorption/ionisation-time of flight mass spectrometry profiling--a pilot study.
    Remmerbach TW; Maurer K; Janke S; Schellenberger W; Eschrich K; Bertolini J; Hofmann H; Rupf S
    Oral Oncol; 2011 Apr; 47(4):278-81. PubMed ID: 21354855
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less.
    Lozano MD; Echeveste JI; Abengozar M; Mejías LD; Idoate MA; Calvo A; de Andrea CE
    Arch Pathol Lab Med; 2018 Mar; 142(3):291-298. PubMed ID: 29494220
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
    Vannitamby A; Hendry S; Irving L; Steinfort D; Bozinovski S
    Lung Cancer; 2019 Aug; 134():233-237. PubMed ID: 31319986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).
    Heeke S; Benzaquen J; Hofman V; Ilié M; Allegra M; Long-Mira E; Lassalle S; Tanga V; Salacroup C; Bonnetaud C; Fayada J; Gazoppi L; Ribeyre L; Castelnau O; Garnier G; Cattet F; Nanni I; de Fraipont F; Cohen C; Berthet JP; Leroy S; Poudenx M; Marquette CH; Denis MG; Barlesi F; Hofman P
    Clin Lung Cancer; 2020 Jan; 21(1):56-65.e8. PubMed ID: 31519454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.
    Shevchenko VE; Arnotskaya NE; Zaridze DG
    Eur J Mass Spectrom (Chichester); 2010; 16(4):539-49. PubMed ID: 20625202
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.